8-K Announcements
6Material company update
May 29, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
Apr 30, 2026·SEC
Enveric Biosciences, Inc.(ENVB)Earnings, Financials & Key Ratios
ENVB•NASDAQ
Price updated Jun 19, 2026
AboutEnveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Show more
- Revenue$0
- EBITDA-$9M+7.8%
- Net Income-$12M-26.7%
- EPS (Diluted)-36.24+84.1%
- ROE-420.48%+22.1%
ENVB Key Insights
Enveric Biosciences, Inc. (ENVB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Profits declining 12.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ENVB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENVB Price & Volume
Enveric Biosciences, Inc. (ENVB) stock price & volume — 10-year historical chart
Loading chart...
ENVB Growth Metrics
Enveric Biosciences, Inc. (ENVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.81%
Return on Capital
10 Years-157.02%
5 Years-263.81%
3 Years-344.92%
Last Year-304.12%
ENVB Recent Earnings
Enveric Biosciences, Inc. (ENVB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (73%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$1.08
—
Rev
—
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.85+101.5%
$55.80
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$10.81+82.8%
$63.00
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$11.64+81.5%
$63.00
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.08 | — |
| Q2 2026 | Mar 27, 2026 | $0.85vs $55.80+101.5% | — |
| Q4 2025 | Nov 14, 2025 | $10.81vs $63.00+82.8% | — |
| Q3 2025 | Aug 14, 2025 | $11.64vs $63.00+81.5% | — |
Based on last 12 quarters of dataView full earnings history →
ENVB Peer Comparison
Enveric Biosciences, Inc. (ENVB) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 LSCC | 21.06B | 153.72 | 6893.27 | 2.72% | 3.46% | 2.79% | 0.11 | |
 SILO | 5.54M | 6.12 | -0.82 | -67.17% | -88.41% | |||
 DRUG | 470.81M | 60.66 | -48.07 | -20.72% | 0.00 | |||
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare ENVB vs Peers
Enveric Biosciences, Inc. (ENVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENVB Income Statement
Enveric Biosciences, Inc. (ENVB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 48.59M | 43M | 39.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | 34.44% | -11.51% | -7.17% | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 38.36M | 34.01M | 31.76M | 120.87K | 681.61K | 435.2K | 408.03K | 337.49K | 200.86K | 157.07K |
COGS % of Revenue | 78.93% | 79.11% | 79.58% | - | - | - | - | - | - | - |
Gross Profit | 10.24M▲ 0% | 8.98M▼ 12.3% | 8.15M▼ 9.3% | -120.87K▼ 101.5% | -681.61K▼ 463.9% | -435.2K▲ 36.2% | -408.03K▲ 6.2% | -337.49K▲ 17.3% | -200.86K▲ 40.5% | -157.07K▲ 0% |
Gross Margin % | 21.07% | 20.89% | 20.42% | - | - | - | - | - | - | - |
Gross Profit Growth % | 56.62% | -12.25% | -9.27% | -101.48% | -463.91% | 36.15% | 6.24% | 17.29% | 40.48% | - |
Operating Expenses | 21.73M | 13.7M | 14.48M | 5.5M | 25.26M | 19.53M | 16.04M | 9.29M | 8.57M | 8.06M |
OpEx % of Revenue | 44.71% | 31.86% | 36.27% | - | - | - | - | - | - | - |
Selling, General & Admin | 18.51M | 10.79M | 12.21M | 5.32M | 20.47M | 11.5M | 8.79M | 6.45M | 5.79M | 5.68M |
SG&A % of Revenue | 38.09% | 25.11% | 30.59% | - | - | - | - | - | - | - |
Research & Development | 0 | 0 | 0 | 174.08K | 4.79M | 8.03M | 7.25M | 2.84M | 2.78M | 2.38M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 1.08M | 88.16K | 2.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -11.97M▲ 0% | -7.15M▲ 40.3% | -6.32M▲ 11.5% | -5.62M▲ 11.2% | -25.94M▼ 361.9% | -19.96M▲ 23.1% | -16.45M▲ 17.6% | -9.63M▲ 41.4% | -8.77M▲ 8.9% | -8.22M▲ 0% |
Operating Margin % | -24.63% | -16.62% | -15.85% | - | - | - | - | - | - | - |
Operating Income Growth % | -122.51% | 40.3% | 11.5% | 11.19% | -361.87% | 23.06% | 17.6% | 41.44% | 8.91% | - |
EBITDA | -8.75M | -4.24M | -4.06M | -5.5M | -25.26M | -19.53M | -16.04M | -9.29M | -8.57M | -8.06M |
EBITDA Margin % | -18.01% | -9.87% | -10.17% | - | - | - | - | - | - | - |
EBITDA Growth % | -117.82% | 51.53% | 4.32% | -35.39% | -359.62% | 22.71% | 17.85% | 42.05% | 7.76% | 10.5% |
D&A (Non-Cash Add-back) | 3.22M | 2.9M | 2.27M | 120.87K | 681.61K | 435.2K | 408.03K | 337.49K | 200.86K | 157.07K |
EBIT | -10.89M | -9.82M | -4.52M | -6.42M | -56.42M | -19.95M | -17.26M | -9.57M | -8.77M | -8.22M |
Net Interest Income | -575.04K | -729.9K | -691.14K | -444.81K | -10.31K | -5.24K | -3.71K | 219 | -106 | -411 |
Interest Income | 0 | 0 | 0 | 445 | 10 | 5 | 0 | 219 | 0 | 274 |
Interest Expense | 575.04K | 729.9K | 691.14K | 445.25K | 10.32K | 5.25K | 3.71K | 0 | 106 | 685 |
Other Income/Expense | -11.47M | -10.55M | 1.11M | -1.25M | -30.49M | 4.05K | -814.38K | 66.21K | 2.46K | -409 |
Pretax Income | -11.47M▲ 0% | -10.55M▲ 8.0% | -5.22M▲ 50.6% | -6.86M▼ 31.6% | -56.43M▼ 722.1% | -19.96M▲ 64.6% | -17.26M▲ 13.5% | -9.57M▲ 44.6% | -8.77M▲ 8.3% | -8.22M▲ 0% |
Pretax Margin % | -23.6% | -24.53% | -13.07% | - | - | - | - | - | - | - |
Income Tax | -2.39M | 6.35M | 388.66K | 0 | -7.45M | -1.49M | 28.91K | 8.93K | 3.36M | 0 |
Effective Tax Rate % | 20.86% | -60.18% | -7.45% | 0% | 13.21% | 7.45% | -0.17% | -0.09% | -38.3% | 0% |
Net Income | -9.07M▲ 0% | -16.9M▼ 86.2% | -5.6M▲ 66.8% | -6.86M▼ 22.5% | -48.98M▼ 613.5% | -18.5M▲ 62.2% | -17.29K▲ 99.9% | -9.57M▼ 55272.4% | -12.13M▼ 26.7% | -8.22M▲ 0% |
Net Margin % | -18.67% | -39.3% | -14.04% | - | - | - | - | - | - | - |
Net Income Growth % | -226.35% | -86.2% | 66.84% | -22.5% | -613.46% | 62.22% | 99.91% | -55273.21% | -26.7% | 11.64% |
Net Income (Continuing) | -9.07M | -16.9M | -5.6M | -6.86M | -48.98M | -18.47M | -17.29M | -9.57M | -12.13M | -8.22M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 19.04K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 885.03K | 0 | 0 | 0 | 0 |
EPS (Diluted) | -36347.76▲ 0% | -42616.68▼ 17.2% | -2543.88▲ 94.0% | -666.00▲ 73.8% | -1244.28▼ 86.8% | -156.00▲ 87.5% | -97.08▲ 37.8% | -228.48▼ 135.4% | -36.24▲ 84.1% | -5.44▲ 0% |
EPS Growth % | -184.63% | -17.25% | 94.03% | 73.82% | -86.83% | 87.46% | 37.77% | -135.35% | 84.14% | 99.81% |
EPS (Basic) | -36347.76 | -42616.68 | -2543.88 | -666.00 | -1244.28 | -87.72 | -97.08 | -228.48 | -36.24 | - |
Diluted Shares Outstanding | 250 | 396 | 2.2K | 9.59K | 39.36K | 173.19K | 179.92K | 41.91K | 334.72K | 1.51M |
Basic Shares Outstanding | 250 | 396 | 2.2K | 9.59K | 39.36K | 210.63K | 210.63K | 41.91K | 334.72K | 1.51M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ENVB Balance Sheet
Enveric Biosciences, Inc. (ENVB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.64M | 10.06M | 7.6M | 2.28M | 17.74M | 18.43M | 3.58M | 2.73M | 4.94M | 5.38M |
Cash & Short-Term Investments | 4.88M | 1.37M | 431.4K | 1.58M | 17.36M | 17.72M | 2.29M | 2.24M | 4.68M | 4.91M |
Cash Only | 4.88M | 1.37M | 431.4K | 1.58M | 17.36M | 17.72M | 2.29M | 2.24M | 4.68M | 4.91M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 8.84M | 7.87M | 6.38M | 0 | 0 | 0 | 224.61K | 0 | 0 | 0 |
Days Sales Outstanding | 66.39 | 66.82 | 58.38 | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 38 |
Other Current Assets | 924.27K | 818.6K | 718.53K | 700.71K | 0 | 159.78K | 567.6K | 0 | 43.25K | 0 |
Total Non-Current Assets | 37.55M | 19.58M | 17.41M | 1.82M | 8.98M | 1.12M | 718.31K | 347.96K | 159.23K | 146.37K |
Property, Plant & Equipment | 95.05K | 58.89K | 83.13K | 0 | 470.73K | 741.3K | 507.38K | 305.78K | 159.23K | 119.93K |
Fixed Asset Turnover | 511.25x | 730.12x | 480.16x | - | - | - | - | - | - | 0.00x |
Goodwill | 21.9M | 13.73M | 13.73M | 0 | 1.59M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 9.47M | 5.78M | 3.58M | 1.82M | 6.92M | 379.69K | 210.93K | 42.18K | 0 | 0 |
Long-Term Investments | -6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.44K |
Total Assets | 52.2M▲ 0% | 29.64M▼ 43.2% | 25.01M▼ 15.6% | 4.1M▼ 83.6% | 26.72M▲ 552.2% | 19.55M▼ 26.8% | 4.3M▼ 78.0% | 3.08M▼ 28.3% | 5.1M▲ 65.3% | 5.52M▲ 0% |
Asset Turnover | 0.93x | 1.45x | 1.60x | - | - | - | - | - | - | 0.00x |
Asset Growth % | 32.12% | -43.22% | -15.63% | -83.62% | 552.18% | -26.82% | -78.01% | -28.31% | 65.32% | 23.23% |
Total Current Liabilities | 30.37M | 14.69M | 14.38M | 681.25K | 2.08M | 4M | 2.34M | 1.49M | 918.4K | 460.68K |
Accounts Payable | 5.32M | 4.38M | 4.7M | 681.25K | 683.39K | 463.27K | 1.22M | 521.75K | 581.02K | 280.31K |
Days Payables Outstanding | 50.67 | 46.98 | 53.97 | 2.06K | 365.95 | 388.55 | 1.09K | 564.28 | 1.06K | 1.5K |
Short-Term Debt | 4.8M | 5.21M | 4.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | -2.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 20.24M | 3.8M | 737.79K | 0 | 0 | 1.76M | 350.72K | 3.09K | 251.51K | 123.57K |
Current Ratio | 0.48x | 0.68x | 0.53x | 3.35x | 8.51x | 4.61x | 1.53x | 1.84x | 5.38x | 11.67x |
Quick Ratio | 0.48x | 0.68x | 0.53x | 3.35x | 8.51x | 4.61x | 1.53x | 1.84x | 5.38x | 11.67x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.46K |
Total Non-Current Liabilities | 2.38M | 4.19M | 0 | 0 | 2.33M | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 68.86K | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 4.19M | 0 | 0 | 2.26M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 32.75M | 18.88M | 14.38M | 681.25K | 4.41M | 4M | 2.34M | 1.49M | 918.4K | 460.68K |
Total Debt | 7.18M | 5.21M | 4.88M | 0 | 176.3K | 63.82K | 0 | 0 | 0 | 0 |
Net Debt | 2.3M | 3.84M | 4.45M | -1.58M | -17.18M | -17.66M | -2.29M | -2.24M | -4.68M | -4.91M |
Debt / Equity | 0.37x | 0.48x | 0.46x | - | 0.01x | 0.00x | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.61x |
Interest Coverage | -18.94x | -13.45x | -6.55x | -14.42x | -5469.31x | -3801.13x | -4655.56x | - | -82777.81x | -12000.31x |
Total Equity | 19.44M▲ 0% | 10.76M▼ 44.7% | 10.62M▼ 1.3% | 3.42M▼ 67.8% | 22.31M▲ 553.1% | 15.56M▼ 30.3% | 1.96M▼ 87.4% | 1.59M▼ 18.6% | 4.18M▲ 162.3% | 5.06M▲ 0% |
Equity Growth % | 66.71% | -44.67% | -1.28% | -67.84% | 553.05% | -30.26% | -87.42% | -18.58% | 162.28% | 119.34% |
Book Value per Share | 77779.20 | 27169.44 | 4821.40 | 356.20 | 566.69 | 89.83 | 10.87 | 38.01 | 12.48 | 3.35 |
Total Shareholders' Equity | 19.44M | 10.76M | 10.62M | 3.42M | 22.31M | 14.67M | 1.96M | 1.59M | 4.18M | 5.06M |
Common Stock | 181.63K | 423.29K | 25.22K | 100.95K | 6.52K | 20.78K | 27.39K | 6.78K | 10.62K | 18.88K |
Retained Earnings | -15M | -34.48M | -40.51M | -11.76M | -60.74M | -79.21M | -96.5M | -106.07M | -114.85M | -116.48M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 36.88K | 87K | 60.01K | -181.28K | -30.8K | -536.73K | -569.75K | -594.52K | -580.04K | -587.06K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 885.03K | 0 | 0 | 0 | 0 |
ENVB Cash Flow Statement
Enveric Biosciences, Inc. (ENVB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.74M | -2.57M | -647.86K | -3.89M | -11.46M | -17.15M | -14.09M | -7.73M | -8.14M | -8.01M |
Operating CF Margin % | -5.64% | -5.97% | -1.62% | - | - | - | - | - | - | - |
Operating CF Growth % | -1.36% | 6.4% | 74.75% | -500.25% | -194.63% | -49.65% | 17.8% | 45.18% | -5.38% | -119.69% |
Net Income | -11.16M | -16.9M | -2.41M | -6.86M | -48.98M | -18.47M | -17.29M | -9.57M | -8.77M | -8.22M |
Depreciation & Amortization | 3.22M | 2.9M | 0 | 120.87K | 681.61K | 435.2K | 408.03K | 337.49K | 200.86K | 157.07K |
Stock-Based Compensation | 7.08M | 1.25M | 0 | 1.98M | 12.6M | 2.62M | 2.15M | 1.56M | 827.32K | 722.15K |
Deferred Taxes | -2.39M | 6.35M | 0 | 0 | -7.45M | -1.5M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.06M | 4.86M | 738.5K | 1.25M | 30.51M | -9.3K | 813.88K | 372.21K | -101.8K | -79.63K |
Working Capital Changes | -539.78K | -1.03M | 1.02M | -369.5K | 1.19M | -217.66K | -174.75K | -423.24K | -295.94K | -585.89K |
Change in Receivables | -778.54K | 967.03K | 1.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 620.79K | -2.1M | 222.68K | 0 | 383.2K | 263.69K | -103.85K | -834.63K | -413.86K | -529.97K |
Cash from Investing | -808.88K | -3.64M | 0 | -44.14K | 2.19M | -584.16K | 11.67K | 0 | 0 | 0 |
Capital Expenditures | -4.84K | 0 | 0 | -44.14K | -864.72K | -584.16K | -5.18K | 0 | 0 | 0 |
CapEx % of Revenue | 0.01% | - | - | - | - | - | - | - | - | - |
Acquisitions | -804.04K | -3.65M | 0 | 0 | 3.06M | 958.04K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -804.04K | 6.42K | 0 | 0 | -675 | -958.04K | 16.85K | 0 | 0 | 0 |
Cash from Financing | 7.05M | 2.69M | 560K | 5.53M | 24.9M | 18.18M | -1.34M | 7.67M | 10.58M | 8.63M |
Debt Issued (Net) | 0 | -1.98M | 538K | 1.67M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 4.9M | 6.33M | 0 | 488K | 21.61M | 17.22M | -1.05M | 3.37M | 10.58M | 8.63M |
Dividends Paid | -2.09B | -2.09T | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.08M | 0 | 0 |
Other Financing | 2.09B | -1.66M | 22K | 3.37M | 3.29M | 958.04K | -291.08K | 4.3M | 0 | 0 |
Net Change in Cash | 3.5M▲ 0% | -3.51M▼ 200.2% | -1.33M▲ 62.2% | 1.53M▲ 215.6% | 15.78M▲ 928.0% | 367.88K▼ 97.7% | -15.44M▼ 4295.9% | -46.95K▲ 99.7% | 2.44M▲ 5289.4% | 614.33K▲ 0% |
Free Cash Flow | -2.75M▲ 0% | -2.57M▲ 6.6% | -647.86K▲ 74.7% | -3.93M▼ 507.1% | -12.32M▼ 213.3% | -17.73M▼ 43.9% | -14.1M▲ 20.5% | -7.73M▲ 45.2% | -8.14M▼ 5.4% | -8.01M▲ 0% |
FCF Margin % | -5.65% | -5.97% | -1.62% | - | - | - | - | - | - | - |
FCF Growth % | 57.05% | 6.56% | 74.75% | -507.06% | -213.31% | -43.89% | 20.48% | 45.2% | -5.38% | -6.48% |
FCF per Share | -10982.54 | -6478.52 | -294.08 | -410.15 | -313.05 | -102.38 | -78.37 | -184.36 | -24.32 | -5.30 |
FCF Conversion (FCF/Net Income) | 0.30x | 0.15x | 0.12x | 0.57x | 0.23x | 0.93x | 815.10x | 0.81x | 0.67x | 0.97x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 9.51K | 5K | 0 | 0 |
ENVB Key Ratios
Enveric Biosciences, Inc. (ENVB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -58.34% | -111.89% | -52.42% | -97.81% | -380.82% | -97.74% | -0.2% | -539.57% | -420.48% | -220.99% |
Return on Invested Capital (ROIC) | -48.45% | -29.5% | -31.98% | -49.83% | -558.88% | -990.44% | - | - | - | 2030.45% |
Gross Margin | 21.07% | 20.89% | 20.42% | - | - | - | - | - | - | - |
Net Margin | -18.67% | -39.3% | -14.04% | - | - | - | - | - | - | - |
Debt / Equity | 0.37x | 0.48x | 0.46x | - | 0.01x | 0.00x | - | - | - | 0.00x |
Interest Coverage | -18.94x | -13.45x | -6.55x | -14.42x | -5469.31x | -3801.13x | -4655.56x | - | -82777.81x | -12000.31x |
FCF Conversion | 0.30x | 0.15x | 0.12x | 0.57x | 0.23x | 0.93x | 815.10x | 0.81x | 0.67x | 0.97x |
Revenue Growth | 34.44% | -11.51% | -7.17% | -100% | - | - | - | - | - | - |
Related:ENVB Dividend History·ENVB Revenue History·ENVB Price History·ENVB P/E History·ENVB Financial Ratios·ENVB Institutional Holders
ENVB SEC Filings & Documents
Enveric Biosciences, Inc. (ENVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
ENVB Frequently Asked Questions
Enveric Biosciences, Inc. (ENVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Enveric Biosciences, Inc. (ENVB) grew revenue by 0.0% over the past year. Growth has been modest.
Enveric Biosciences, Inc. (ENVB) reported a net loss of $8.2M for fiscal year 2025.
Dividend & Returns
Enveric Biosciences, Inc. (ENVB) has a return on equity (ROE) of -420.5%. Negative ROE indicates the company is unprofitable.
Enveric Biosciences, Inc. (ENVB) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.